HeartSciences ($HSCS) Look To Dominate $25 Billion AI ECG Industry
By Tom White, Benzinga Contributor It’s unsurprising to reveal that heart disease is one of the leading causes of death worldwide, with more than 50,000
April 30, 2024
Millions of ECGs are performed every week, however for decades these tests have largely remained unchanged. Conventional ECGs are easy and quick to perform however unfortunately do not detect most heart disease conditions.
Artificial Intelligence-Enhanced Electrocardiography (AI-ECG) is set to transform cardiovascular medicine. AI-ECG allows previously unseen disease to be identified and radically expands the clinical usefulness of an ECG.
Known as the silent killer, heart attacks can occur unexpectedly, and heart disease symptoms* often do not appear until an acute stage. Today’s challenge is to detect and treat disease early before, symptoms occur.
AI-ECG provides frontline healthcare with more effective diagnoses and referrals, ensuring earlier treatment and better outcomes.
19.9 million deaths from cardiovascular disease (CVD) in 2021***
* Center for Disease Control and Prevention. Heart Disease Facts
** The Center for Advancing Health (CFAH). Heart Disease Statistics in the US (2024 Update)
*** American Heart Association. 2024 Heart Disease and Stroke Statistics Update Fact Sheet
By Tom White, Benzinga Contributor It’s unsurprising to reveal that heart disease is one of the leading causes of death worldwide, with more than 50,000
Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease Source:
Publications Abstract Background Recent guidelines propose N-terminal pro-B-type natriuretic peptide (NT-proBNP) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes mellitus (T2DM).
Publications Originally published29 Dec 2023 https://doi.org/10.1161/JAHA.123. 31671 Journal of the American Heart Association. 2024;13:e031671 Link to article: Quantitative Prediction of Right Ventricular Size and Function From the ECG | Journal of
Publications Joshua Lampert, Akhil Vaid, William Whang, Jacob Koruth, Marc A. Miller, Marie-Noelle Langan, Daniel Musikantow, Mohit Turagam, Abhishek Maan, Iwanari Kawamura, Srinivas Dukkipati, Girish N. Nadkarni, and Vivek Y. Reddy Abstract Background Premature ventricular complexes (PVCs) are prevalent and, although often
HeartSciences’ AI-ECG products are currently in development and not commercially available in the United States.
wavECG and wavEKG are trademarks of HeartSciences.
MV-WBSTE-002 Rev A